TaiGen Biotechnology Overview
- Year Founded
-
2001
- Status
-
Public
- Employees
-
51
- Stock Symbol
-
4157
- Investments
-
2
- Share Price
-
$0.23
- (As of Friday Closing)
TaiGen Biotechnology General Information
Description
TaiGen Biopharmaceuticals Holdings Ltd is mainly engaged in the research and development of new drugs, including the selection of drug candidates, pre-IND trials and clinical trials. Its operating segment includes development, research and sales of new drugs, and other. The majority of the revenue is generated from development, research and sales of new drugs.
Contact Information
Website
www.taigenbiotech.comCorporate Office
- 7th Floor, 138 Shin Ming Road
- Neihu District
- Taipei, 114
- Taiwan
Corporate Office
- 7th Floor, 138 Shin Ming Road
- Neihu District
- Taipei, 114
- Taiwan
TaiGen Biotechnology Stock Performance
As of 20-Nov-2026, TaiGen Biotechnology’s stock price is $0.23. Its current market cap is $161M with 712M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.23 | $0.24 | $0.22 - $0.52 | $161M | 712M | 1.07M |
TaiGen Biotechnology Financials Summary
As of 30-Sep-2026, TaiGen Biotechnology has a trailing 12-month revenue of $8.33M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 170,150 | 279,714 | 219,618 | 330,943 |
| Revenue | 8,326 | 8,318 | 4,695 | 3,953 |
| EBITDA | 5,095 | 1,863 | (967) | 4,875 |
| Net Income | 4,846 | 1,448 | (1,202) | 4,390 |
| Total Assets | 32,541 | 37,324 | 35,710 | 40,023 |
| Total Debt | 315 | 1,574 | 1,785 | 2,431 |
TaiGen Biotechnology Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
TaiGen Biotechnology Comparisons
Industry
Financing
Details
TaiGen Biotechnology Competitors (25)
One of TaiGen Biotechnology’s 25 competitors is Merck & Co., a Corporation company based in Rahway, NJ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Merck & Co. | Corporation | Rahway, NJ | ||||
| Gesynta Pharma | Venture Capital-Backed | Stockholm, Sweden | ||||
| Gilead | Formerly VC-backed | Foster City, CA | ||||
| Genentech | Formerly VC-backed | South San Francisco, CA | ||||
| Amgen | Formerly PE-Backed | Thousand Oaks, CA |
TaiGen Biotechnology Patents
TaiGen Biotechnology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023296430-A1 | Pharmaceutical composition comprising a cap-dependent endonuclease inhibitor | Active | 27-Jun-2022 | ||
| AU-2023296430-B2 | Pharmaceutical composition comprising a cap-dependent endonuclease inhibitor | Active | 27-Jun-2022 | ||
| EP-4543451-A1 | Pharmaceutical composition comprising a cap-dependent endonuclease inhibitor | Pending | 27-Jun-2022 | ||
| EP-4543451-A4 | Pharmaceutical composition comprising a cap-dependent endonuclease inhibitor | Pending | 27-Jun-2022 | ||
| US-20230414612-A1 | Pharmaceutical composition comprising a cap-dependent endonuclease inhibitor | Pending | 27-Jun-2022 | A61K9/1652 |
TaiGen Biotechnology Signals
TaiGen Biotechnology Investments (2)
TaiGen Biotechnology’s most recent deal was a Later Stage VC with GPCR Therapeutics. The deal was made on 28-Nov-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| GPCR Therapeutics | 28-Nov-2023 | Later Stage VC | Drug Discovery | ||
| Dongguan HEC TaiGen Biopharmaceuticals | 10-Jan-2017 | Joint Venture | Pharmaceuticals |
TaiGen Biotechnology ESG
Risk Overview
Risk Rating
Updated February, 28, 2025
29.24 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,271
Rank
Percentile
Pharmaceuticals
Industry
of 908
Rank
Percentile
Biotechnology
Subindustry
of 434
Rank
Percentile
TaiGen Biotechnology FAQs
-
When was TaiGen Biotechnology founded?
TaiGen Biotechnology was founded in 2001.
-
Where is TaiGen Biotechnology headquartered?
TaiGen Biotechnology is headquartered in Taipei, Taiwan.
-
What is the size of TaiGen Biotechnology?
TaiGen Biotechnology has 51 total employees.
-
What industry is TaiGen Biotechnology in?
TaiGen Biotechnology’s primary industry is Drug Discovery.
-
Is TaiGen Biotechnology a private or public company?
TaiGen Biotechnology is a Public company.
-
What is TaiGen Biotechnology’s stock symbol?
The ticker symbol for TaiGen Biotechnology is 4157.
-
What is the current stock price of TaiGen Biotechnology?
As of 20-Nov-2026 the stock price of TaiGen Biotechnology is $0.23.
-
What is the current market cap of TaiGen Biotechnology?
The current market capitalization of TaiGen Biotechnology is $161M.
-
What is TaiGen Biotechnology’s current revenue?
The trailing twelve month revenue for TaiGen Biotechnology is $8.33M.
-
Who are TaiGen Biotechnology’s competitors?
Merck & Co., Gesynta Pharma, Gilead, Genentech, and Amgen are some of the 25 competitors of TaiGen Biotechnology.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process